Immune Cycle-Based Strategies for Cancer Immunotherapy

被引：38

作者：

Li, Yanhua ^{[1
]}

Liu, Xiaohan ^{[1
]}

Zhang, Xia ^{[1
]}

Pan, Wei ^{[1
]}

Li, Na ^{[1
]}

Tang, Bo ^{[1
]}

机构：

[1] Shandong Normal Univ, Inst Mol & Nano Sci,Minist Educ, Collaborat Innovat Ctr Funct Probes Chem Imaging, Key Lab Mol & Nano Probes,Coll Chem Chem Engn & M, Jinan 250014, Peoples R China

来源：

ADVANCED FUNCTIONAL MATERIALS | 2021年 / 31卷 / 50期

基金：

中国国家自然科学基金;

关键词：

cancer; cancer immune cycle; immune response; immunotherapy; intelligent strategies; IMMUNOGENIC CELL-DEATH; TUMOR-ASSOCIATED MACROPHAGES; CD8(+) T-CELLS; DENDRITIC CELLS; B-CELLS; ALTERNATIVE ACTIVATION; SILICA NANOPARTICLES; ANTIGEN PRESENTATION; DELIVERY; ANTITUMOR;

D O I：

10.1002/adfm.202107540

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

The immune system is composed of immune organs, immune cells, and immunoactive substances, which plays a vital role in antitumor immunity in cancer immunotherapy. During the process of the antitumor immune response, many factors are involved in the cancer immune cycle. Therefore, developing intelligent strategies based on the steps of the cancer immune cycle to elicit the immune responses for enhanced cancer immunotherapy is of great significance. In this review, the key factors in each step of the cancer immune cycle are discussed, and then, the intelligent therapeutic strategies for modulating the immune surveillance against cancer are highlighted. Considering the demand for cancer immunotherapy in clinic, some suggestions for constructing new intelligent strategies are also put forward, which will make antitumor immunity more effective and advance the development of cancer immunotherapy.

引用

页数：27

共 244 条

[1] Asymmetric mesoporous silica nanoparticles as potent and safe immunoadjuvants provoke high immune responses [J].

Abbaraju, Prasanna Lakshmi ;

Jambhrunkar, Manasi ;

Yang, Yannan ;

Liu, Yang ;

Lu, Yao ;

Yu, Chengzhong .

CHEMICAL COMMUNICATIONS, 2018, 54 (16) :2020-2023

[2] Asymmetric Silica Nanoparticles with Tunable Head-Tail Structures Enhance Hemocompatibility and Maturation of Immune Cells [J].

Abbaraju, Prasanna Lakshmi ;

Meka, Anand Kumar ;

Song, Hao ;

Yang, Yannan ;

Jambhrunkar, Manasi ;

Zhang, Jun ;

Xu, Chun ;

Yu, Meihua ;

Yu, Chengzhong .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2017, 139 (18) :6321-6328

[3] B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma [J].

Abramson, Hanley N. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) :1-24

[4] A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy [J].

Awuah, Samuel G. ;

Zheng, Yao-Rong ;

Bruno, Peter M. ;

Hemann, Michael T. ;

Lippard, Stephen J. .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2015, 137 (47) :14854-14857

[5] Immunobiology of dendritic cells [J].

Banchereau, J ;

Briere, F ;

Caux, C ;

Davoust, J ;

Lebecque, S ;

Liu, YT ;

Pulendran, B ;

Palucka, K .

ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :767-+

[6] Dendritic cells and the control of immunity [J].

Banchereau, J ;

Steinman, RM .

NATURE, 1998, 392 (6673) :245-252

[7] Dendritic cells as therapeutic vaccines against cancer [J].

Banchereau, J ;

Palucka, AK .

NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :296-306

[8] Macrophage polarization in bacterial infections [J].

Benoit, Marie ;

Desnues, Benoit ;

Mege, Jean-Louis .

JOURNAL OF IMMUNOLOGY, 2008, 181 (06) :3733-3739

[9] Cancer immunotherapy: A treatment for the masses [J].

Blattman, JN ;

Greenberg, PD .

SCIENCE, 2004, 305 (5681) :200-205

[10]

Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]

← 1 2 3 4 5 6 7 8 9 10 →